Haddad RI, Harrington K, Tahara M, Ferris RL, et al. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. J Clin Oncol 2022 Dec 6:JCO2200332. doi: 10.1200/JCO.22.00332.
PMID: 36473143